Dr John Anderson

John retired as Head of the Institute for Animal Health, Pirbright Laboratory, UK and Head of the World Reference Laboratory for Morbilliviruses in 2008 and is now a consultant. John joined Animal Virus Research Institute, Pirbright (now Institute for Animal Health) in 1968. Over the next 40 years, he was seconded to Kenya for 6 years and subsequently worked on the development, validation and commercialization of diagnostic assays for foot and mouth disease, bluetongue, rinderpest and peste des petits ruminants viruses. John had a major involvement in technology transfer to developing countries and the highly successful Global Rinderpest Eradication Programme. He is a designated OIE expert on bluetongue and rinderpest. John was awarded the MBE for services to animal health in 2003.


Professor Wendy Barclay

Wendy holds the Chair in Influenza Virology at Imperial College, London and the Chair of Virology for the Society of General Microbiology. Wendy graduated in Natural Sciences from Cambridge University. After postgraduate study at the Common Cold Unit in Salisbury with Dr David Tyrrell FRS, Wendy joined Professor Jeffrey Almond at the University of Reading. In 1992 Wendy moved to the Mount Sinai Medical Center in New York where Professor Peter Palese had just made a breakthrough that facilitated the recovery of recombinant influenza virus from cloned cDNA. Wendy was the first to adapt the technique for the study of type B influenza viruses. Wendy returned to the University of Reading in 1995 and worked on influenza viruses there for 12 years. In May 2007 she moved with her group to take up a Chair in Influenza Virology at Imperial College.


Professor Tony Cass

Tony is Professor of Chemical Biology, Deputy Director and Research Director (Bionanotechnology) in the Institute of Biomedical Engineering at Imperial College, London and a Fellow of the Royal Society of Chemistry. He trained originally as a chemist with degrees from the Universities of York and Oxford. His research interests are in the field of analytical biotechnology and particularly in the use of protein engineering and design to produce new reagents for biosensors and bioanalysis. Tony pioneered the use of synthetic electron transfer mediators for enzyme biosensors and his work in this area led to the development of the first electronic blood glucose measuring system, commercialised by MediSense Inc. (now part of Abbott Diagnostics), and was awarded the Royal Society’s Mullard Medal (with Professor HAO Hill FRS and Dr MJ Green).


Professor Steven Myint

Steven is Chairman of Plexpress Oy, a Finnish biotech company, and Director of Moewin Associates which provides consultancy to the health and biopharmaceutical industries. He is a physician with broad experience at board and executive level in academia, biopharmaceutical and the third sector. He is a former Professor and Dean of Medicine & Health at the University of Surrey and Professor of Microbiology & Immunology at the University of Leicester. He has been a global Medical Director at GlaxoSmithKline and Senior Vice-President for R&D/Chief Medical Officer at BTG International. He is also a former Senior Independent Director in the NHS and Board Member of Care International, and was executive chairman of Onmedica Group Ltd and Onmedica India Private Ltd. He is currently a Director of the European Federation of Neurological Associations, consultant to several organisations in the medical and financial worlds and member of several national and international advisory boards. He has authored over 120 peer reviewed publications and 6 books. He is a Fellow or Member of several societies, including the Institute of Knowledge Transfer, the Royal College of Physicians and the Royal Society of Medicine. He has an international reputation in infectious disease research and vaccine development.


Professor David Rowlands

David is Emeritus Professor of Molecular Virology at the University of Leeds. David’s research career started at the BBSRC Institute for Animal Health, Pirbright laboratory where he worked for almost 20 years, mostly on Foot-and-Mouth Disease virus. This was followed by 12 years experience in industry, at the Wellcome Foundation. Finally he moved into academia as Professor of Molecular Virology at the University of Leeds. He continues to be research active in Leeds after formally retiring from the chair in 2005. During his career he has worked on many aspects of virology including basic studies of the mechanisms of virus replication, determination of molecular structures of virus particles, replication proteins and RNAs, antigenic structures and vaccine development.


Professor Nigel Slater

Nigel holds the 1999 Chair of Chemical Engineering within the Department of Chemical Engineering at the University of Cambridge, and leads the BioScience Engineering Group which addresses the development of novel strategies for the manufacture, formulation and delivery of biotherapeutics. Currently, the group is investigating methods to improve long term stability of biopharmaceuticals by lyophilization and new adsorptive methods for purification, and also targeted delivery strategies for DNA and viral therapeutics. Nigel gained industrial experience of biopharmaceutical manufacturing whilst in Wellcome plc (1990-95), and subsequently as a non-executive director and scientific advisor for Cobra BioManufacturing plc (2002-2008). He has been a member of the Commission on Human Medicines, MHRA Biologicals and Vaccines Expert Advisory Group.


Dr John Tite

John is now working as an independent consultant advising both biotech and venture capital companies, having recently retired from GSK. John graduated from University College London in Zoology and then did his PhD at the Middlesex Hospital Medical School in the field of B cell tolerance. During post-doctoral fellowships at the Medical Schools at Bristol and Yale Universities, he focused on the study of T cell differentiation and activation. From 1986, John worked at the Wellcome Foundation, and then GlaxoWellcome and GSK where he led a variety of discovery programmes in the fields of vaccines and therapeutic antibodies. John played a key role in the establishment of GSK’s biopharmaceuticals business unit and when he retired from GSK at the end of 2008 he was head of the Discovery Biology group for the GSK Biopharm CEDD, taking biopharm programmes from target to proof of concept.


Sir Gregory Winter FRS

Greg is a pioneer of therapeutic monoclonal antibodies, inventor and entrepreneur. Greg is currently Deputy Director of the Division of Protein and Nucleic Acid Chemistry, of the Laboratory of Molecular Biology, Cambridge, an institution of the UK Medical Research Council. He invented techniques both to humanise (1986) and then to make fully human antibodies for therapeutic uses, and his technology is used in over 65% of the antibody products in development or on the market. Greg was a founder of Cambridge Antibody Technology (1989), an early company involved in antibody engineering (acquired by AstraZeneca), and also founded Domantis (2000), which pioneered the use of domain antibodies (acquired by GSK). Greg has won several international prizes, and received a knighthood in 2004. Greg is a Fellow of Trinity College, University of Cambridge.


Professor Jeffrey Almond

Jeff is an Oxford Martin Visiting Fellow with the Oxford Martin Programme on Vaccines and was Former Vice President and Head of Discovery Research and External R&D at Sanofi Pasteur and Visiting Fellow at the William School of Pathology, University of Oxford.  He was lecturer at the University of Leicester from 1979-85 and Professor of Microbiology at the University of Reading 1985-99. He has published extensively, especially in the field of Virology. His scientific contributions include the first demonstration that a single gene can determine host range – a finding highly relevant to understanding evolution of new pandemic strains; completion of the genetic map of an avian influenza virus, and the first detailed description of the proteins of Influenza B virus. He has also made major contributions to our understanding of polio virus and its vaccines.